Title:
ANGIOGENESIS INHIBITOR-CONJUGATED ANTI-C3B ANTIBODY OR ANTI-C5 ANTIBODY AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/132547
Kind Code:
A1
Abstract:
The present invention relates to a fusion protein comprising an anti-C3b antibody or an anti-C5 antibody and an angiogenesis inhibitor, and a composition for treating eye diseases, particularly macular degeneration, by using same. The protein may not only inhibit complement-related pathways, but can also efficiently regulate angiogenesis. Therefore, the fusion protein dimer can be effectively used to treat and prevent complement-related diseases, particularly eye diseases such as macular degeneration, and thus has high industrial applicability.
Inventors:
CHUNG EU DDEUM (KR)
RYU SOOMIN (KR)
KIM DONGGEON (KR)
CHANG JIHOON (KR)
LEE BYOUNG CHUL (KR)
RYU SOOMIN (KR)
KIM DONGGEON (KR)
CHANG JIHOON (KR)
LEE BYOUNG CHUL (KR)
Application Number:
PCT/KR2022/021371
Publication Date:
July 13, 2023
Filing Date:
December 27, 2022
Export Citation:
Assignee:
KANAPH THERAPEUTICS INC (KR)
International Classes:
C07K16/18; A61K38/00; A61K39/00; A61P27/02; C07K14/71; C12N15/62
Foreign References:
| US20200115443A1 | 2020-04-16 | |||
| KR20120088551A | 2012-08-08 | |||
| KR20080110800A | 2008-12-19 | |||
| US20150079084A1 | 2015-03-19 | |||
| KR20190138636A | 2019-12-13 |
Attorney, Agent or Firm:
RYU, Jong Woo et al. (KR)
Download PDF:
Previous Patent: BYPASS ARRANGEMENT FOR A HEAT EXCHANGER OF A REFRIGERANT CIRCUIT OF A MOTOR VEHICLE
Next Patent: DISSOLVER
Next Patent: DISSOLVER